Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroimmunology, Solid Tumor, and Hematological Malignancies Development.
CNTN1 Target Overview & Key Mutations
CNTN1 (Contactin-1) is a GPI-anchored cell adhesion molecule of the immunoglobulin superfamily, encoded by gene CNTN1 (UniProt Q12860). The extracellular region comprises three Ig-like C2-type domains (Ig1-Ig3) and six fibronectin type-III domains (FNIII1-6). Key naturally occurring mutations include a somatic mutation found in a colorectal cancer sample (VAR_035506), and two single-nucleotide polymorphisms (rs1056020 and rs11553341) documented in dbSNP. These variants highlight CNTN1's relevance in both oncogenic transformation and population-level diversity, underscoring the need for sequence-verified reagents in assay development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CNTN1 drug discovery and diagnostic development. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CNTN1 ECD-Fc Fusion Protein (Wild-type & Mutant variants available) GPI-anchored ectodomain (Ig1-6/FNIII domains), High purity (>95%), Endotoxin <1EU/µg, Sequence Verified, HEK293 Expressed (Native Glycosylation) |
View CNTN1 Products |
| Gene Delivery | CNTN1 Lentivirus Premade Particles Full-length ORF (GPI-anchored) for stable cell line construction, preserving native conformation |
View CNTN1 Products |
| Benchmark Ab | Anti-CNTN1 (Sequence of Reference mAb) Recombinant positive control for binding and blocking assays |
View CNTN1 Products |
| Validator | CNTN1 siRNA Set For knockdown verification and specificity controls |
View CNTN1 Products |
| Related Target: CNTN2 (TAG-1) | Closest paralog (65% identity), Critical for selectivity screening against off-target binding | View CNTN2 Products |
| Related Target: CNTN4 (BIG-2) | Shared Ig domain architecture, Required for subfamily counter-screening assays | View CNTN4 Products |
| Related Target: CNTNAP1 (Caspr) | Cis-complex partner at paranodes; modulates CNTN1 surface presentation and axonal localization | View CNTNAP1 Products |
| Related Target: NFASC (Neurofascin) | Forms the core paranodal complex with CNTN1; crucial for CIDP autoantibody profiling | View NFASC Products |
| Related Target: TNC (Tenascin-C) | Major ECM ligand; stromal co-targeting strategy to disrupt tumor niche adhesion | View TNC Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational epitope preservation (CIDP autoantibodies) | HEK293 Expressed (Native Glycosylation) ensures proper autoantibody recognition |
| Subfamily selectivity (CNTN2/3/4/5/6 cross-reactivity) | Ortholog panel proteins (Human/Mouse/Cyno) strictly verified by mass spec; available CNTN2, CNTN4 for cross-reactivity panels |
| GPI-anchor conformation integrity for native binding | Full-length CNTN1 Lentivirus for stable cell lines; preserves membrane-associated folding and glycosylation patterns |
| ADC internalization efficiency screening | High-purity (>95%) ECD-Fc with verified Fc-silencing options for confocal/internalization assays |
| False positive elimination in binding screens | Sequence-verified siRNA sets for CNTN1-specific knockdown validation in target cells |
| Lack of reliable controls | Reference recombinant antibodies included for assay standardization |
| On-target specificity in tumor models | Validated siRNA included for precise EMT/Metastasis knockdown verification |
Live CNTN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CNTN1-targeted therapeutics and diagnostics is intensifying across three major therapeutic domains. In neuroimmunology, pathogenic IgG4 autoantibodies against CNTN1 disrupt paranodal junctions, driving a subset of chronic inflammatory demyelinating polyneuropathy (CIDP). Major players (Argenx, UCB) leverage FcRn inhibitors and B-cell depletion, with CNTN1 autoantibody levels serving as critical companion diagnostics. In solid tumor oncology, CNTN1 is emerging as a driver of epithelial-mesenchymal transition (EMT) and metastasis in cancers such as prostate, lung, and gastric. Preclinical biotechs are developing monoclonal antibodies and ADCs targeting CNTN1 to block invasion pathways. In hematological malignancies, CNTN1 has gained attention as an alternative target in multiple myeloma, especially after resistance to BCMA-directed therapies. First-in-class ADCs and bispecific engagers are in early clinical phases, focusing on internalization efficiency and combination with IMiDs. The next wave of R&D will require high-purity, conformationally intact reagents to validate target engagement and selectivity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic / Biomarker | Neuroimmunology Labs | CIDP / Neuropathy | Autoantibody Detection (Need High-Purity, HEK293 ECD-Fc) |
| FcRn Inhibitors | Argenx, UCB | Autoimmune Neuropathy | Pathogenic IgG clearance tracking (Need Native Antigens) |
| Monoclonal Antibody (Solid Tumor) | Preclinical Biotech | Metastatic Solid Tumors (Prostate, Lung, Gastric) | Invasion/EMT Assays (Need pure ECD proteins) |
| ADC (Hematology) | Emerging biotechs, Oncology innovators | Multiple Myeloma (Relapsed/Refractory) | Internalization Assay (Requires high-purity ECD-Fc for binding confirmation and pH-sensitive dye conjugation studies) |
| Bispecific Engager | Immuno-oncology developers | Solid Tumors (Neuroblastoma), Multiple Myeloma | Heterodimer Validation (Need cross-reactive antibodies against human/cyno CNTN1 for toxicology bridging) |
| CAR-T / Cell Therapy | Cell therapy companies | Hematological Malignancies | Cell Surface Density Quantification (Requires lentivirus-stable cell lines with physiological expression levels) |
| siRNA / Gene Therapy | Preclinical Biotech | Prostate/Lung Cancers | Pathway Validation (Need knockdown verification sets) |